Unilateral Adrenalectomy for Primary Aldosteronism Linked to CKD, Gout Risks Chelsie Derman

Published Date: 14 Jan 2026

A 20-year population study found unilateral adrenalectomy raises long-term risks of CKD and gout in primary aldosteronism.

Read Full News

Latest News

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus

5 Rheumatology Headlines You Missed in December 2025

5 Rheumatology Headlines You Missed in December 2025

Q4 2025 Recap: Rheumatology News and Updates

Q4 2025 Recap: Rheumatology News and Updates

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point

Rheumatology in 2025: Year in Review

Rheumatology in 2025: Year in Review

Rheumatoid Arthritis in 2025: Year in Review

Rheumatoid Arthritis in 2025: Year in Review

Todays Updates

7 Rheumatology Headlines You Missed in October 2025 Victoria Johnson

The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know Victoria Johnson

A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.

Unseen Symptoms: Cognitive Decline Reveals Quality-of-Life Impacts of SLE, with Carla Cuda, PhD Carla Marie Cuda, PhD

New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.

This Year in Medicine 2025: Recognizing Top Advances in Healthcare HCPLive Editorial Staff

Explore groundbreaking advancements in healthcare as 2025 concludes, featuring expert insights and dynamic multimedia.

5 Rheumatology Headlines You Missed in November 2025 Victoria Johnson

This rheumatology month in review emphasizes new data from the ACR Convergence.

Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT Victoria Johnson

New data support firsekibart's efficacy over colchicine for preventing acute gout flares.

Lingdolinurad Demonstrates Dose-Dependent Serum Uric Acid Reductions Victoria Johnson

A new study reveals ligdolinurad effectively lowers uric acid levels in gout patients, showcasing promising safety and tolerability results.

Todays Updates

7 Rheumatology Headlines You Missed in October 2025 Victoria Johnson

The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know Victoria Johnson

A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.

Unseen Symptoms: Cognitive Decline Reveals Quality-of-Life Impacts of SLE, with Carla Cuda, PhD Carla Marie Cuda, PhD

New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.

This Year in Medicine 2025: Recognizing Top Advances in Healthcare HCPLive Editorial Staff

Explore groundbreaking advancements in healthcare as 2025 concludes, featuring expert insights and dynamic multimedia.

5 Rheumatology Headlines You Missed in November 2025 Victoria Johnson

This rheumatology month in review emphasizes new data from the ACR Convergence.

Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT Victoria Johnson

New data support firsekibart's efficacy over colchicine for preventing acute gout flares.

Lingdolinurad Demonstrates Dose-Dependent Serum Uric Acid Reductions Victoria Johnson

A new study reveals ligdolinurad effectively lowers uric acid levels in gout patients, showcasing promising safety and tolerability results.

Latest News

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus

5 Rheumatology Headlines You Missed in December 2025

Q4 2025 Recap: Rheumatology News and Updates

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point

Rheumatology in 2025: Year in Review

Rheumatoid Arthritis in 2025: Year in Review

News All Time

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

High Rates of Overactive Bladder Found in Women With Fibromyalgia

High Rates of Overactive Bladder Found in Women With Fibromyalgia

TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief

TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief

Patient Attitudes Key to Effective Hyperuricemia Self-Management

Patient Attitudes Key to Effective Hyperuricemia Self-Management

Lingdolinurad Demonstrates Dose-Dependent Serum Uric Acid Reductions

Lingdolinurad Demonstrates Dose-Dependent Serum Uric Acid Reductions

LEVI-04 Improves Pain, Function in Knee Osteoarthritis, with Philip Conaghan, MBBS, PhD Philip Conaghan, MBBS, PhD

Conaghan discussed the potential of LEVI-04 for knee osteoarthritis at ACR 2025.

Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT

Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

What’s Next for Dapirolizumab Pegol Following Lupus Phase 3 Trial, With Ed Vital, MD Ed Vital, MD

Phase 3 data show dapirolizumab pegol improved remission and disease stability in lupus; a second trial and patient-reported outcomes are now underway.

Lupus Disease Activity Correlates With Cognition, With Carla Marie Cuda, PhD

Lupus Disease Activity Correlates With Cognition, With Carla Marie Cuda, PhD

Ianalumab Provides Clinical Benefit in Lupus Phase 2 Trial, With Ed Vital, MD

Ianalumab Provides Clinical Benefit in Lupus Phase 2 Trial, With Ed Vital, MD

Addressing Fibromyalgia Sleep and Pain With TNX-102 SL Approval: Q&A With Philip Mease, MD Philip J. Mease, MD

Mease discussed his hopes for the new approval's impact on the fibromyalgia field.

Q3 2025 Recap: 7 Top FDA Approvals to Know Victoria Johnson

Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields.

Q3 2025 Recap: Rheumatology News and Updates Victoria Johnson

Q3 2025 saw a number of exciting approvals and data on promising therapies in development.

7 Rheumatology Headlines You Missed in September 2025 Victoria Johnson

The rheumatology month in review emphasizes new approvals and the latest comparative research.

Bridging the Treatment Gap in Pediatric Psoriasis and PsA With Guselkumab, With Vimal H. Prajapati, MD Vimal H. Prajapati, MD

Prajapati discussed the impact of the expanded approval of guselkumab to pediatric PsO and psoriatic arthritis.

Recommended News For You

Alarm Over Pharma-China Link; Taking Screening to the People; Agriculture and Cancer

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

Hybrid imaging test combines antibody and radioisotope for early lung cancer detection

Papillary thyroid cancer: New markers offer hope for tailored treatment

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

Antitumor mRNA-based vaccines show potential against gastric cancer metastasis

Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity

Recommended Articles For You

A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities 

Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care 

Understanding the HAS-BLED Score: What It Is and Why It Matters  

Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Unified Neuro/Psych Residency Program: New Proposal.

2.

Ignoring Colonoscopy Advice; Dry Mouth Acupuncture; Inflamed Tongue, Then Cancer.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

AI is equally capable of reading breast cancer scans as human radiologists.

5.

Unlocking the potential of targeted therapies for multiple myeloma

1.

Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology

2.

Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment

3.

Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients

4.

AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined

5.

HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

3.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

4.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

5.

Navigating the Complexities of Ph Negative ALL - Part XVI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot